ClinicalTrials.gg
RecruitingNCT07390851Updated Feb 5, 2026

Magnesium Sulfate as an Adjuvant to Lidocaine in MPDS Trigger Point Injections Assessed by VAS and sEMG.

An interventional study of Lidocaine 2% (preservative-free, without vasoconstrictor) and Lidocaine 2% + Magnesium Sulfate 10% (combination) in Myofascial Pain Dysfunction Syndrome, sponsored by Cairo University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-02-05.

Sponsored by Cairo University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Fibromyalgia by Cairo University — 9 open to participants now, 9 under way, none of them phase 3. Fibromyalgia · Cairo University.

Planned enrollment
13th of 13
28 · median 52
Started
2025
the only one that year
No phase
13 of 13
9 open now
Registered
9th of 13
by date

Among the 13 studies in Fibromyalgia by Cairo University, this one is the 13th largest by planned enrollment, is the only one that started in 2025, is one of 13 with no phase, and was the 9th registered.

Fibromyalgia

1,245 studies on the registry are indexed under Fibromyalgia; 256 are open to participants now.

Browse Fibromyalgia studies →

Open to participants now

9 of the 13 studies in Fibromyalgia by Cairo University are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 161 Fibromyalgia studies recruiting now, 51 (32%) set no upper age limit and 96 (60%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Fibromyalgia by Cairo University, or all of them as a file.
02

Study summary

Two groups of patients diagnosed with Myofascial Pain Dysfunction Syndrome (MPDS) will be included in this study. One group will receive trigger point injections of lidocaine alone. The other group will receive trigger point injections of lidocaine combined with magnesium sulfate. The study aims to compare the effectiveness of both treatments in reducing pain and improving muscle function. Patients will be assessed using a pain scale (VAS) and surface electromyography (sEMG) to measure muscle activity.

Read the detailed description

This randomized clinical trial aims to evaluate whether adding magnesium sulfate to lidocaine in trigger point injections provides better pain relief and muscle relaxation in patients with Myofascial Pain Dysfunction Syndrome (MPDS) compared to lidocaine alone.

Participants diagnosed with MPDS will be randomly assigned into one of two groups:

Group 1 (Control Group): Trigger point injection of lidocaine 2% Group 2 (Intervention Group): Trigger point injection of lidocaine 2% combined with magnesium sulfate 10% Each participant will receive injections in the identified myofascial trigger points. Pain during injection and after injection will be assessed using the Visual Analog Scale (VAS). Muscle activity will be measured using surface electromyography (sEMG) at specific time points during rest and muscle contraction.

The study will compare the changes in pain scores and EMG readings between the two groups to determine whether magnesium sulfate enhances the analgesic and muscle-relaxing effects of lidocaine. The results of this study may help improve treatment strategies for MPDS and provide evidence for using magnesium sulfate as an adjuvant to lidocaine in trigger point injections.

03

Conditions studied

  • Myofascial Pain Dysfunction Syndrome

Browse trials for

Keywords

  • Trigger points injection
  • Myofascial Pain Dysfunction Syndrome (MPDS)
  • Magnesium Sulfate
  • Surface Electromyography
  • Visual Analog Scale
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age between 18 and 70 years.
  2. Clinical diagnosis of Myofascial Pain Dysfunction Syndrome (MPDS).
  3. Presence of active myofascial trigger points in accessible muscles (e.g., masseter, temporalis, upper trapezius).
  4. Pain duration ≥ 3 months.
  5. Pain intensity ≥ 4 on the Visual Analog Scale (VAS).
  6. Noprior trigger point injection in the affected area within the past 3 months.
  7. Ability and willingness to provide .
  8. Compliance with study visits and procedures

Exclusion criteria

Exclusion Criteria:

  1. Known allergy or to Lidocaine, Magnesium Sulfate, or related agents.
  2. Current use of anticoagulants or history of bleeding disorders.
  3. Systemic or local infection at or near the injection site.
  4. History of fibromyalgia, central pain syndromes, or cancer-related pain.
  5. Major psychiatric illnesses (e.g., schizophrenia, severe depression).
  6. Recent surgery or trauma to the head, neck, or upper back (\<6 months).
  7. Use of analgesics (NSAIDs, opioids) within 5 days before intervention.
  8. Severe systemic diseases:- Uncontrolled diabetes mellitus- Liver or kidney failure- Severe cardiovascular conditions.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
28 participants (estimated)

Study arms

  • Active comparator
    Lidocaine injection

    2%preservative-free without vasocostrictor injectable solution, 1.8 ml per injection point.

    Drug: Lidocaine 2% (preservative-free, without vasoconstrictor)

  • Experimental
    Injection of Magnesium sulfate with Lidocaine

    10% injectable solution (100 mg/ml), from certified supplier. Approx. 3.8 ml per point (1.8 ml Lidocaine + 2 ml MgSO₄)

    Drug: Lidocaine 2% + Magnesium Sulfate 10% (combination)

Interventions

  • DrugLidocaineStudies of LidocaineLidocaine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Using 25-27G sterile disposable needle, intramuscular injection of 2%preservative-free solution of lidocaine without vasocostrictor, 1.8 ml at the most painful trigger points with "Fast-in, fast out" or "peppering" method and inject the solution slowly.

  • DrugLidocaine 2% + Magnesium Sulfate 10% (combination)

    Drug page: LidocaineStudies of LidocaineLidocaine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Using 25-27G sterile disposable needle, intramuscular injection of 2%preservative-free solution of lidocaine without vasocostrictor mixed with 10%magnesium sulphate , Approx. 3.8 ml per point (1.8 ml Lidocaine + 2 ml MgSO₄) at the most painful trigger points with "Fast-in, fast out" or "peppering" method and inject the solution slowly.

06

What researchers measure

Primary outcomes

  1. Pain reduction.

    Pain intensity will be assessed using the Visual Analogue Scale (VAS) ranging from 0 to 10 cm, where 0 indicates no pain and 10 indicates worst imaginable pain.

    Time frame: Baseline, 1week, 2 weeks post-injection.

  2. Muscle activity improvement.

    Muscle activity will be assessed using surface electromyography (sEMG) by measuring Maximum Voluntary Contraction (MVC) in microvolts (µV). Higher values indicate improved muscle activity.

    Time frame: Baseline, 1 week, 2 weeks post-injection

Secondary outcomes

  1. Pain experienced during injection

    Pain during injection will be assessed immediately after injection using the Visual Analogue Scale (VAS) ranging from 0 to 10 cm, where 0 indicates no pain and 10 indicates worst imaginable pain.

    Time frame: Immediately after injection

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Leitch J, Webb A, Pudwell J, Chamberlain S, Henry R, Nitsch R. Magnesium-Based Trigger Point Infiltrations Versus Local Anaesthetic Infiltrations in Chronic Pelvic Myofascial Pain: A Randomized, Double-Blind, Controlled Study. J Obstet Gynaecol Can. 2022 Aug;44(8):877-885. doi: 10.1016/j.jogc.2022.02.129. Epub 2022 Mar 24. PubMed 35339694 ↗
  • Refahee SM, Mahrous AI, Shabaan AA. Clinical efficacy of magnesium sulfate injection in the treatment of masseter muscle trigger points: a randomized clinical study. BMC Oral Health. 2022 Sep 19;22(1):408. doi: 10.1186/s12903-022-02452-3. PubMed 36123724 ↗

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared. This is an academic thesis-based study, and the data contain sensitive personal and clinical information. Data access is restricted by institutional policies and ethical approval requirements. De-identified aggregate results will be reported in publications.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Nov 2026, 12 months after the start.

Of 439 non-industry interventional studies with no phase under Fibromyalgia, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 31. This study's planned 12 months is below that.

Counting every sponsor, half of 452 studies reached it within 15 months; a quarter within 6 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2026
First posted
Feb 5, 2026
StartActual
Nov 26, 2025
Primary completionEst.
Nov 26, 2026
CompletionEst.
Nov 26, 2026
Last update
Feb 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07390851
Lead sponsor
Cairo University
Responsible party
Maii Emad Abdelazeem (Principle investigator, Cairo University) — Principal investigator
First posted
Feb 5, 2026
Start date
Nov 26, 2025
Primary completion
Nov 26, 2026 (estimated)
Completion
Nov 26, 2026 (estimated)
Last update
Feb 5, 2026

Study contacts

Maii E Abdelazeem, BSc
Contact
Maii.emad@dentistry.cu.edu.eg
+20 1013988933
Khaled A Elhayes, PhD
Contact
+20 1030000360
Maii E Abdelazeem, Bsc
principal investigator · Faculty of Oral & Dental Medicine, Cairo University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lidocaine

Start the discussion